Key Takeaways Shares of SpringWorks Therapeutics soared on Monday following a report that German medical firm Merck KGaA ...

Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases ...

Merck KGaA is in advanced talks to acquire U.S. drugmaker Springworks Therapeutics, potentially impacting the healthcare sector with a sizable move in its cancer treatment pipeline. Springworks' stock ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Merck KGaA (MKGAY) confirms “advanced discussions” with Springworks Therapeutics (SWTX) regarding a potential acquisition. “Merck also confirms ...

After a slow 2024, dealmaking in the U.S. healthcare sector is picking up. Springworks has a market value of $3 billion.

SpringWorks Therapeutics shares rose 36% after Reuters reported Germany's Merck KGaA is in advanced talks to buy the company. Shares were trading around $54.66. The stock is up 16% over the last year ...

-- Germany's Merck KGaA is in advanced talks to buy U.S. cancer and rare diseases biotech company Springworks Therapeutics, Reuters says, citing unnamed sources. -- The deal could be finalized in the ...

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...

German healthcare giant Merck KGaA is in advanced talks to acquire U.S.-based Springworks Therapeutics, known for cancer and rare disease treatments. The potential acquisition would enhance Merck's ...